Rhythm Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Maintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming Catalysts
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49
B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
Rhythm Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Positive Prescription Growth and Pipeline Potential
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Rhythm Pharmaceuticals Analyst Ratings
Rhythm Pharmaceuticals Analyst Ratings
Wells Fargo Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Buy Rating Justified by Rhythm Pharmaceuticals' Strong Market Entry and Promising Pipeline
Rhythm Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Rhythm Pharmaceuticals: Expanding Markets and Innovation Fuel Buy Rating Upgrade
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Performance and Market Expansion
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Prescription Growth and Promising Clinical Developments
Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Buy Rating for Rhythm Pharmaceuticals: Anticipated Growth and Strong Performance Led by IMCIVREE in BBS Market
No Data